Extraordinary and unusual measures may be needed to rapidly develop and distribute a vaccine against SARS-CoV-2, but those efforts should not compromise the safety and efficacy of any product that reaches the market, according to the FDA Vaccines and Related Biological Products Advisory Committee.
However, the committee did not make any recommendations for ensuring the products are not compromised.
According to leading patient safety